Cargando…

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer

INTRODUCTION: Immune therapy has shown good results in small-cell lung cancer (SCLC), but the impact of immune microenvironment of the disease is unclear. In this work, we detected expression of programmed death 1 (PD-1), PD-ligand 1 (PD-L1), and other immune biomarkers of cancer. We also analyzed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Chenglong, Zhang, Liping, Zhang, Wei, Liu, Yu, Chen, Bin, Zhao, Sha, Li, Wei, Wang, Lei, Ye, Lingyun, Jia, Keyi, Wang, Hao, Wu, Chunyan, He, Yayi, Zhou, Caicun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342461/ https://www.ncbi.nlm.nih.gov/pubmed/32753888 http://dx.doi.org/10.2147/OTT.S252031

Ejemplares similares

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes
por: He, Yayi, et al.
Publicado: (2017)

Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review
por: Li, Wei, et al.
Publicado: (2020)

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment
por: Wang, Hao, et al.
Publicado: (2019)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

CD39: the potential target in small cell lung cancer
por: Chen, Shanhao, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
por: Buisseret, Laurence, et al.
Publicado: (2016)

Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma
por: Chen, Zihang, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases
por: Sun, Chenglong, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Immunotherapy as a treatment for small cell lung cancer: a case report and brief review
por: Wu, Yan, et al.
Publicado: (2020)

iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2020)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD‐1 inhibitor therapy
por: Fang, Qiyu, et al.
Publicado: (2022)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

CD137, an attractive candidate for the immunotherapy of lung cancer
por: Ye, Lingyun, et al.
Publicado: (2020)

Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8(+) Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer
por: Munari, Enrico, et al.
Publicado: (2021)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes
por: Tian, Guang-Ang, et al.
Publicado: (2021)

Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis
por: Däster, Silvio, et al.
Publicado: (2020)

PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis
por: Li, Min, et al.
Publicado: (2013)

Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression
por: Pötzsch, M., et al.
Publicado: (2020)

PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma
por: Pollari, Marjukka, et al.
Publicado: (2018)

PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
por: Liu, Bin, et al.
Publicado: (2018)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC
por: Liu, Sangtian, et al.
Publicado: (2021)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
por: Higuchi, Rumi, et al.
Publicado: (2019)

PD-L1 Expression and Combined Status of PD-L1/PD-1–Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
por: Han, Jiheun, et al.
Publicado: (2017)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c5p7rn5bd5h2mmct1pdv6ljdfr